The global adapalene market size was estimated at USD 605.5 million in 2025 and is projected to reach USD 789.5 million by 2033, growing at a CAGR of 3.9% from 2026 to 2033. The market is experiencing steady growth due to the increasing prevalence of acne and other dermatological disorders, growing awareness of dermatology treatments, and expanding access to topical retinoid therapies.
Adapalene, a third-generation topical retinoid widely used to treat acne vulgaris, works by regulating skin cell turnover, reducing inflammation, and preventing clogged pores. Because of its strong efficacy and relatively favorable safety profile compared with earlier retinoids, adapalene has become one of the most commonly prescribed topical agents for mild-to-moderate acne and is increasingly incorporated into combination therapies with benzoyl peroxide or antibiotics.
One of the major factors driving demand for adapalene globally is the high and rising prevalence of acne vulgaris. For instance, in May 2025, a study published by MDPI AG on the epidemiology of acne in the current era: trends and clinical implications highlighted that acne remains a highly prevalent inflammatory skin condition worldwide. This condition affects approximately 9.4% of the global population, with increasing incidence observed among both adolescents and adults, particularly women. These epidemiological trends emphasize the growing need for effective acne therapies such as topical retinoids, including adapalene, in dermatological treatment. As a result, acne consistently ranks among the most prevalent skin diseases globally, creating sustained demand for effective pharmacological treatments such as topical retinoids, including adapalene.
In addition to adolescents, adult acne is becoming increasingly common, particularly among women. Dermatological studies indicate that acne is no longer confined to teenage years, with a growing number of individuals experiencing persistent or late-onset acne beyond the age of 25. As per the article published by MDalgorithms Inc. in August 2025, it suggests that around one-fifth of adults aged 25-39 still experience acne, indicating a broader patient population requiring long-term dermatological treatment. This shift toward adult acne prevalence has significantly expanded the addressable market for topical therapies like adapalene, which is frequently used as a maintenance treatment due to its ability to prevent new lesions and control chronic inflammation.
The market is also benefiting from ongoing pharmaceutical innovation and new combination therapies incorporating adapalene. Such product developments are expanding therapeutic options and strengthening the clinical adoption of adapalene as part of multidrug acne management strategies. Furthermore, lifestyle and environmental factors are contributing to the increasing burden of acne worldwide. Rising urban pollution, dietary changes, hormonal imbalances, and stress levels have been associated with worsening acne incidence in many regions. At the same time, the growing influence of social media and increased awareness about skin health and aesthetics have encouraged more individuals to seek dermatological treatment for acne and related conditions. As acne can lead to scarring, pigmentation, and psychological distress, demand for effective treatments such as adapalene continues to rise across both prescription dermatology and over-the-counter skincare segments.
This product will be delivered within 1-3 business days.
Adapalene, a third-generation topical retinoid widely used to treat acne vulgaris, works by regulating skin cell turnover, reducing inflammation, and preventing clogged pores. Because of its strong efficacy and relatively favorable safety profile compared with earlier retinoids, adapalene has become one of the most commonly prescribed topical agents for mild-to-moderate acne and is increasingly incorporated into combination therapies with benzoyl peroxide or antibiotics.
One of the major factors driving demand for adapalene globally is the high and rising prevalence of acne vulgaris. For instance, in May 2025, a study published by MDPI AG on the epidemiology of acne in the current era: trends and clinical implications highlighted that acne remains a highly prevalent inflammatory skin condition worldwide. This condition affects approximately 9.4% of the global population, with increasing incidence observed among both adolescents and adults, particularly women. These epidemiological trends emphasize the growing need for effective acne therapies such as topical retinoids, including adapalene, in dermatological treatment. As a result, acne consistently ranks among the most prevalent skin diseases globally, creating sustained demand for effective pharmacological treatments such as topical retinoids, including adapalene.
In addition to adolescents, adult acne is becoming increasingly common, particularly among women. Dermatological studies indicate that acne is no longer confined to teenage years, with a growing number of individuals experiencing persistent or late-onset acne beyond the age of 25. As per the article published by MDalgorithms Inc. in August 2025, it suggests that around one-fifth of adults aged 25-39 still experience acne, indicating a broader patient population requiring long-term dermatological treatment. This shift toward adult acne prevalence has significantly expanded the addressable market for topical therapies like adapalene, which is frequently used as a maintenance treatment due to its ability to prevent new lesions and control chronic inflammation.
The market is also benefiting from ongoing pharmaceutical innovation and new combination therapies incorporating adapalene. Such product developments are expanding therapeutic options and strengthening the clinical adoption of adapalene as part of multidrug acne management strategies. Furthermore, lifestyle and environmental factors are contributing to the increasing burden of acne worldwide. Rising urban pollution, dietary changes, hormonal imbalances, and stress levels have been associated with worsening acne incidence in many regions. At the same time, the growing influence of social media and increased awareness about skin health and aesthetics have encouraged more individuals to seek dermatological treatment for acne and related conditions. As acne can lead to scarring, pigmentation, and psychological distress, demand for effective treatments such as adapalene continues to rise across both prescription dermatology and over-the-counter skincare segments.
Global Adapalene Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global adapalene market report based on formulation, drug composition, prescription, indication, distribution channel, and region:Formulation Outlook (Revenue, USD Million, 2021-2033)
- Gels
- Creams
- Lotions
Drug Composition Outlook (Revenue, USD Million, 2021-2033)
- Adapalene Monotherapy
- Adapalene Combination Products
Prescription Outlook (Revenue, USD Million, 2021-2033)
- Over-the-Counter (OTC)
- Prescription-based
Indication Outlook (Revenue, USD Million, 2021-2033)
- Acne Vulgaris
- Post-Inflammatory Hyperpigmentation
- Photoaging & Skin Texture Disorders
- Follicular Keratinization Disorders
- Acne Maintenance Therapy
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Adapalene Market Variables, Trends & Scope
Chapter 4. Adapalene Market: Formulation Estimates & Trend Analysis
Chapter 5. Adapalene Market: Drug Composition Estimates & Trend Analysis
Chapter 6. Adapalene Market: Prescription Estimates & Trend Analysis
Chapter 7. Adapalene Market: Indication Estimates & Trend Analysis
Chapter 8. Adapalene Market: Distribution Channel Estimates & Trend Analysis
Chapter 9. Adapalene Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Galderma S.A.
- Glenmark Pharmaceuticals
- Teva Pharmaceuticals
- Sandoz Group AG
- Sun Pharmaceuticals Industries
- Dr. Reddy's Laboratories
- Cipla Limited
- Lupin Limited
- Torrent Pharmaceuticals
- Zydus Lifesciences Limited
- La Roche-Posay
- Niksan Pharmaceutical
- SoliPharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 108 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 605.5 Million |
| Forecasted Market Value ( USD | $ 789.5 Million |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
